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ABSTRACT 
Cancers exhibit a remarkable degree of intratumoral heterogeneity (ITH), which results from complex cellular 
interactions amongst various cell types. This phenomenon provides an opportunity for clonal selection and growth advantages to 
aggressive cancer cell types, resulting in worse prognosis and challenges to anti-cancer therapy. Cell competition is a conserved 
mechanism operational in cellular and organ systems, which allows neighboring cells to compare their relative fitness levels and 
results in the elimination of viable but suboptimal cells. By abuse of this conserved homeostasis mechanism, aggressive cancer 
cell types gain an advantage over normal cell types by achieving traits like increased proliferation, de-differentiation, and 
stemness. This review presents recent evidence that cell competition mechanisms actively participate in the regulation of 
intratumoral cell-cell interactions and thus contribute to ITH, and this process is essential for cancer development and 
progression.   
Classical concepts of cell competition 
Throughout the development and life of an organism, cells are subjected to compromising pressures that impact overall 
intrinsic health, culminating in viable, but suboptimal cells. Cell competition is an evolutionarily conserved fitness sensing 
mechanism that functions to ensure optimum tissue health and homeostasis. Neighboring competing cells compare their relative 
fitness status resulting in the elimination of the suboptimal, less fit cells, “Losers," by the more fit cells, "Winners." Cell 
competition was first identified in Drosophila by Morata and colleagues through a series of landmark experiments on a class of 
dominant mutations called Minutes, which encode ribosomal proteins [1]. The homozygous mutation of Minute gene was 
observed to be lethal, and the heterozygous mutation renders animals viable, but with reduced growth rates and reduced 
cellular proliferation. Mosaic wing disc studies revealed that although viable on their own, Minute+/- clones were eliminated from 
the disc when surrounded by Minute wildtype cells. These results suggested that competing cells can sense growth rates and 
that competition results in the elimination of the slower-growing cells. Interestingly, the final wing compartment size was not 
affected by cell competition, indicating that Minute wildtype clones grew at the expense of mutant clones [2, 3]. Additional 
investigations revealed that elimination of Minute+/- clones by wildtype clones was, in fact, apoptosis dependent [4]. Similar to 
the Drosophila findings, studies in a chimeric mouse model found that cells with a heterozygous mutation in the ribosomal 
protein-encoding L24 gene display impaired ribosome biogenesis, and although viable on their own, were eliminated when 
confronted by wildtype cells [5].  These original findings carved the biological foundation of cell competition, and the most recent 
decades have uncovered several fitness sensing mechanisms and downstream signaling networks governing competitive 
interactions. We now understand that cellular fitness is not solely dependent on cell growth or proliferation rates and that 
multiple complex mechanisms underpin fitness communication and competition. Mechanotransduction, fitness fingerprints, and 
biochemical signaling are among the identified mechanisms that regulate fitness communication and signaling between Winners 
and Losers.   
In this review, we focus on how cell competition may contribute to tumor heterogeneity. We first describe the general role 
of cell competition in cancer, with particular focus on p53 and cMyc, two most frequently altered signaling networks in cancer, 
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which are also well-known cell competition genes. Several other signaling pathways have been identified which play roles in 
fitness communication, and downstream apoptotic versus survival signaling; these pathways are also often altered in cancer.  
Cell competition and cancer 
Cell competition based cell selection has been shown to regulate oncogenic growth [6], and many of its mechanisms 
function in sync with oncogenic pathways. As a fitness surveillance mechanism, cell competition may act to repress the early 
stages of tumorigenesis via effective elimination of mutated, transformed cells by normal, wild-type cells [7-9]. Because of a high 
degree of phenotypic and genetic diversity, a cancer mass functions as an ecosystem formed by a variety of oncogenic, pre-
oncogenic cells at different stages of evolution. These cells compete in these neoplastic ecosystems to gain maximum 
proliferation and growth potential amongst themselves and also with the surrounding microenvironment cells. These 
competitive interactions are now found to be governed by cell competition pathways [10-13]. Thus, the cell competition 
mechanism allows cells to identify, cooperate, or destroy the surrounding cells based on the survival of the fittest dogma. It was 
described that cell competition helps in identification and elimination of the viable but suboptimal cells which carry low fitness 
traits. However, aggressive oncogenic cells can induce death of their surrounding healthy cells, thereby creating space for growth 
and nutrients for achieving neoplastic transformation. This process has similarity to super competition, first described in fly 
imaginal discs expressing different doses of dMyc, where cancer cells hijack canonical fitness surveillance and grow at the 
expense of normal cells, resulting in the formation of cancerous lesions. Transformed cells with supercompetitor phenotype may 
expand at the expense of the surrounding normal epithelial cells but without inducing any detectable histologic abnormalities. 
We are presenting a model demonstrating the role of cell competition in the regulation of cancer growth and metastasis (Figure 
1). 
Role of Myc in the regulation of oncogenic cell pathways 
MYC is one of the most frequently mutated genes and is amplified in a variety of cancers [14]. Taking a specific 
example of breast cancer (BC), high MYC mRNA and c-Myc protein expression are significantly correlated with worse outcome, 
poor prognostic factors, hormone therapy resistance, and chemoresistance [15, 16]. Elevated MYC mRNA is associated with 
Estrogen Receptor negative (ER-) and Progesterone Receptor (PGR)-negative tumors and Triple Negative Breast Cancers (TNBCs). 
Moreover, although no correlation has been found between c-Myc protein expression and ER, PgR or HER2 status, c-Myc protein 
is significantly associated with expression of cytokeratin 5/6, EGFR, and other markers of the basal-like phenotype [15]. 
Regulation of MYC expression in breast cancer is not fully elucidated. MYC is a known estrogen-induced gene [17]. Additionally, 
MYC is the target of several signaling networks including PI3K/Akt/mTOR, RAS/RAF/MAPK, JAK/STAT, and the Wnt pathway, all of 
which are identified regulatory pathways in cell competition. In primary TNBCs, MYC was significantly colocalized with cells with 
stem-like features, including CD44 expression, a marker of stem cells in breast cancer [18]. Moreover, MYC expression is 
heterogeneous within primary TNBCs as well as TNBC cell lines, and this leads to differences in downstream Myc-regulated genes 
and ultimately, varying tumorigenic phenotypes within tumors [18].  MYC functions are specific to the molecular subtypes of 
breast cancer [15]. Interestingly, in ER-  BCs, MYC is associated with the upregulation of several genes involved with glucose 
metabolism and transport. Among these genes, CACFD1 (Flower), an identified fitness fingerprint involved in cell competition 
[19],  was a centralized signaling hub, indicating the existence of a critical signaling network between MYC and CACFD1 [15]. 
Since dMyc in a dose-dependent manner has already been shown to confer super competitor phenotype to cells in imaginal discs 
in drosophila models [20, 21], elevated cMyc activity may be one of the mechanisms by which cancer cells acquire similar 
supercompetitor phenotype, which can also explain for the heterogeneous expression pattern of cMyc in tumors. Dedicated 
research is warranted to elucidate transcriptional and post-transcriptional cMyc regulatory mechanisms, signaling downstream 
of cMyc, and relation with cell competition in ER- subtypes.  
p53 tumor suppressor functions via cell competition mechanisms 
Continuing with the perspective on breast cancer, TP53 is among the top mutated genes in all BC subtypes and 
mutations in TP53 occur in nearly 80% of basal-like BCs [22]. In breast cancer, mutations in p53 are associated with more 
aggressive cases and worse clinical outcome. Loss of heterozygosity in the p53 gene is a frequent occurrence in BC, but nearly 
60% of cases retain a wild-type p53 allele [23]. Even in the absence of p53 mutations, several BC cases subvert p53 activity via 
exclusion from the nucleus [24] or changes in upstream signaling factors such as the activity of ataxia-telangiectasia (ATM) [25] 
and Chk2 [26]. Thus, lost or reduced p53 activity via a variety of mechanisms is frequent in BC. Reduced p53 activity has been 
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found to provide a competitive advantage to cells. In the developing mouse embryo, elevated p53 marks cells as defective and 
p53 acts upstream to reduce mTOR signaling, which is required for cell proliferation and survival. In co-culture of bone 
morphogenic protein receptor 1a deficient (Bmpr1a−/−) mouse embryonic cells with wildtype cells, p53-mediated repression of 
mTOR was observed in the apoptotic Bmp-/- cells [27]. Similarly, it was shown that mild p53 activity in the mouse brain, 
pancreas, lung, and liver, instead of inducing anticancer responses such as cell cycle arrest or apoptosis contributes to non-cell 
autonomous cell competition to ensure tissue fitness [28].  Murine double minute (Mdm)2 and Mdm4 negatively regulate p53 
and their haploid insufficiency results in mild activation of p53. Mdm2+/−Mdm4+/−double-heterozygous embryonic cells exhibit 
slightly higher p53 activation than wild-type cells and are thus out-competed, demonstrating its role in the elimination of unfit 
cells to ensure organ and animal fitness [28]. The hematopoietic stem cells with lower p53 activity dominated the stem cell 
niche, whereas cells with high p53 activity were forced into senescence [29]. Similarly, a recent study by Watanabe and 
colleagues found that when Madin-Darby Canine Kidney (MDCK) epithelial cells expressing cancer-enriched p53R273H or 
p53R175H mutants (gain of function mutations) were surrounded by normal cells, mutant p53 cells underwent necroptosis and 
were eliminated from the epithelial monolayer by basal extrusion [30]. However, when RasG12V-transformed cells coexpressed 
mutant p53, necroptosis did not occur. Similar results were obtained in the human pancreatic duct epithelial six (HPDE6) cell line 
[30]. These results present intriguing evidence that cell competition may play a role in the order of mutation appearance, and 
thus tumor evolution, by the maintenance or propagating specific clones. In the case of p53, mutations in this gene may occur 
subsequent to mutations in genes such as Ras such that cells containing mutant p53 loses its loser status and potentially gain 
winner status. This can also explain for the prevailing view that p53 mutation is a late event in cancer. 
Cell competition between tumor and its microenvironment 
It is now well understood that clinically relevant cancer takes several years in development. In this period, there are 
active competitive interactions between cancer cells and host microenvironment cells [31, 32]. The elimination of the 
microenvironment cells is crucial for the growth and metastasis of cancer. We present a model of an active cancer-stromal 
interface in colon, ovarian, pancreatic, and prostate cancer. The cancer tissue must eliminate the stromal tissue to facilitate 
growth in the affected organ (Figure 2). Evidence of cell competition genes and pathways in the regulation of tumor-
microenvironment relations was recently provided from the backdrop of Myc signaling. Immunohistochemical analysis of human 
colon cancers along the tumor-stroma border revealed that in the p esence of c-Myc-expressing tumor cells, stromal cells 
undergo caspase-dependent apoptosis [33]. Another protein, SPARC, is upregulated in loser cells to provide temporary 
protection against cell death by inhibiting caspase activity [34]. In cancer, SPARC expression and function appears to be cancer-
specific, but select cancers show increased SPARC expression along the tumor-stroma border [35]. Recently the role of Hippo 
signaling and its downstream transcription factor, Tead, in the regulation of cell competition and fate of fibroblasts was 
demonstrated [36]. Fibroblasts with genetically suppressed Tead activity behaved as losers and were eliminated when co-
cultured with wild type cells, whereas increased Tead activity imparted a super-competitor like phenotype to these cells that 
eliminated wild type cells [36]. This competition axis is very similar to the Yki–Sd and Myc pathway in Drosophila imaginal discs 
[37, 38]. In cancer, Tead promotes oncogenesis via activation of oncogenic genes, such as CTGF, Cyr61, Myc, and Gli2 [39]. It will 
be interesting and clinically relevant to analyze the expression of Tead in the tumor-stroma intersections and compare with the 
central region of the tumor far away from the stroma.  
Cell competition between cancer cells within an oncogenic mass 
Elimination of loser cells is accompanied by a concomitant gain in the proliferation of super competitors. An evolving 
tumor is characterized by robust proliferation of specific populations balanced by senescence and apoptosis of others [40]. For 
example, injection of the MDA-MB-468 cell line, a triple-negative metastatic breast cancer cell line, into mice results in large 
tumors with slow growth rates. However, these slow-growing tumors still exhibited high proliferation rates based on robust Ki-67 
staining and BrdU incorporation. 
Further analysis showed that a select population of cells were apoptotic, indicating that increased proliferation was 
balanced by apoptosis [41]. This explains an active mechanism for the selection of aggressive or supercompetitive cancer cells 
from the available pool, which renders cancer more aggressive with time (Figure 3). Thus, cell competition offers a clinically 
relevant explanation for the growth patterns of human tumors. The critical point to note is the concept of super competitor cells; 
these are the cells which acquire mutations or activate genetic or signaling pathways which provide them with growth 
advantages. Here we are describing some of the known mechanisms from cell competition research which might be involved in 
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providing cancer cells with such selection advantages. In Drosophila, mutations leading to activation of dMyc [20], and Wg [42] 
genes and inactivation of Hpo [43], have been reported to confer a supercompetitor status to cells. In mammals inactivating 
mutations in Hippo [44], and Notch [45], as well as activating mutations in Myc [46] result in supercompetitors. We have recently 
demonstrated that Flower gene isoform switching is another mechanism of achieving supercompetitor phenotype [47].  
Cell competition and tumoral heterogeneity 
Historically, cancer research has focused on cell-autonomous changes which result in aberrant cellular activity 
summarized as the hallmarks of cancer. However, there is increasing appreciation for how non-cell autonomous factors affect 
the survival, growth, and proliferation of cancer cells, and thereby their function and contribution to the tumor. A hallmark of 
cell competition is that relative fitness, rather than absolute, determines Winner versus Loser status. In a tumor, competitive 
interactions would select for more aggressive clones and subclones at the expense of less fit clones, as well as normal host cells. 
In this regard, cell competition is analogous to the concept of survival of the fittest, but at the cellular level. Ecological principles 
have often been integrated into the theoretical frameworks proposed to explain cancer initiation and progression. In the clonal 
evolution model of cancer, first proposed by Peter Nowell in 1976, tumors originate from a single cell with a genetic mutation 
that conferred enhanced fitness and subsequent mutations followed throughout the lifespan of cancer [48].  In this model, 
cancer cells follow Darwinian evolution, and the fate of a clone is governed by survival of the fittest. The inherent genomic 
instability of cancer cells provides the source of genetic diversity and pressures from the microenvironment drive the selection of 
fitter cells. We present a model to depict how the fitness of cells in host organs can affect tumor growth and metastasis (Figure 
4). Importantly, neither cancer initiation nor progression are static, but are instead highly dynamic processes and thus relative 
clonal and cellular fitness changes over time. The ever-changing landscape of cancer ultimately generates a heterogeneous 
tumor with multiple distinct genotypes and phenotypes. This raises the question of how cell-cell interactions shape the tumor 
population over the realms of space and time and to what extent cell competition actively shapes tumor dynamics. 
Common genetic mechanisms regulating cell competition and tumor heterogeneity 
Tumor heterogeneities can be at hierarchical, genomic/molecular, epigenetic, spatial, metabolic, cell cycle, epithelial to 
mesenchymal transition (EMT), and immune environment levels [49-53].  Spatial heterogeneity may be achieved through either 
cell competition where dominant clones are expected to drive the extinction of other subclones or interdependence between 
subclones where paracrine factors, such as growth factors, produced by one clone help the proliferation of the other. This 
concept has been demonstrated using cancer cells that produce insulin-like growth factor II (IGF-II) and those who do not (IGF-II-
/- cells). While IGF-II-/-, cells showed a lower proliferation rate than IGF-II+/+ cells when grown separately, in co-culture, IGF-II-/- 
cells grew faster than IGF-II+/+ cells and this increased proliferation was dependent on IGF-II. In this case, cell competition is a 
controlled process where IGF-II-/- cells are dominant clones, which limit the growth but do not extinguish IGF-II+/+ clones [54]. 
This type of mutual dependency results in stable heterogeneity. However, as the tumor progresses, the dominant clone may 
achieve independence from the subclones through the accumulation of additional mutations, signaling pathway activation, and 
autocrine action of growth factors. For example, in glioblastoma, tumor cells expressing higher levels of Yes-associated protein 
(YAP) outcompete low-YAP expressing clones to achieve clonal dominance [55]. The master regulator YAP is known to regulate 
cell competition outcomes, thus establishing links between these processes [9, 56]. The decision to acquire a dominant or loser 
clone phenotype may occur immediately after cell division. When proliferating cells complete mitosis, a fraction of newborn 
daughter cells immediately re-enter the cell cycle, while the remaining cells enter transient or persistent quiescence. Maternally 
transmitted DNA damage-induced p53 protein or mitogen-induced Cyclin D1 mRNA would determine the cell fate [57]. Those 
with increased Cyclin D1 would proliferate to become dominant clone over time. This possibly explains why aberration in Cyclin 
D1 is more common in a variety of cancers [58].  
The emmergence of next-generation sequencing technologies, as well as in-depth lineage tracing studies, has provided 
novel insight into tumor heterogeneity. Whole-genome and exome single-cell sequencing in parallel with single copy profiling in 
matched normal and tumor single nuclei from an ER+ breast cancer and TNBC ductal carcinoma revealed that no two single 
cancer cells are genetically identical, and both cancer types contained a large number of subclonal and de novo mutations 
present at low frequencies (<10%) [59]. Perhaps these rare subclonal mutations are integral to the different phenotypic 
responses observed in response to spatial changes in microenvironment pressures, survival from chemotherapy-induced 
selection sweeps and evasion of immune cells. Single-cell sequencing can identify co-existing genomic changes within a single 
tumor, thereby delineating tumor heterogeneity at an even higher resolution than bulk tumor sequencing. The combination of 
Jo
urn
al 
Pre
-pr
oo
f
Parker et. al. 
 5 
bulk tumor analysis and single-cell analysis reveals clonal evolution and co-existence of independent genomic populations at the 
single-cell level. Recently, single-cell whole-genome sequencing of EGFR-amplified glioblastomas identified two distinct 
oncogenic EGFR variants within one tumor. 
Further functional characterizations indicated that overexpression of individual variants in neural stem cells resulted in 
tumors that differed in growth rates, and sensitivity to various EGFR tyrosine kinase inhibitors [60]. In Drosophila, overexpression 
of EGFR in combination with miR-8 transforms wing disc epithelial cells into supercompetitors that induce apoptosis in 
neighboring wild-type cells, followed by engulfment of apoptotic cells, ultimately resulting in neoplasia and metastasis [61]. 
These results can explain why EGFR mutations/overexpression are highly prevalent in a variety of cancers, as the heterogeneous 
expression of EGFR variants would theoretically contribute to competition among clones and the eventual emergence of clones 
that are resistant to EGFR inhibitors.  
Impact of cancer-microenvironment competition on tumor heterogeneity 
Clonal heterogeneity and cellular genetic heterogeneity are generated over the lifetime of cancer as a result of a series 
of genetic and epigenetic alterations. This phenotypic and genotypic heterogeneity generates the possibility for competitive 
interactions between cancer and host cells as well as between cancer cells. Within a growing tumor, cells must compete for 
space, nutrients, oxygen, and blood supply. Therefore, the overall fitness of the cell is determined not only by cell-autonomous 
factors but also by the ability of the cell to respond to and adapt to the tumor microenvironment (TME). Cell-cell interactions can 
be competitive or cooperative, but the context and outcome strongly depend on the local environment and resource availability. 
Although not a cancer model, essential lessons in cell-cell interactions can be gained from a recent study using the model 
adaptive radiation of the bacterium Pseudomonas fluorescens. Herein, authors found that under high resource competition, 
intraspecies (within-species) competition was associated with increased diversity, but strong interspecific (between-species) 
competition reduced overall diversification. 
Interestingly, weak interspecific competition enhanced intraspecific competition and resulted in higher diversification 
[62]. Similarly, in a tumor comprised of multiple cell types and clones and subclones, the degree and outcome of competitive 
interactions would depend on differences in fitness and environmental constraints such as space and resources. Undoubtedly, 
the spatial heterogeneity of the TME plays vital roles in clonal selection. It is well-established that the TME plays critical roles in 
tumor growth and metastasis and remains a significant obstacle in cancer treatment. The TME is composed of a heterogeneous 
population of cells, including fibroblasts, immune cells, endothelial cells, adipocytes, pericytes, as well as extracellular matrix 
components [63]. Thus far, studies of mammalian cell competition have primarily focused on competitive interactions between 
epithelial cells, and whether cell competition occurs between cells of non-identical origin remains to be uncovered. In this 
context, recent work has shown competition between non-epithelial cells such as fibroblasts [44], cardiomyocytes [64], and 
hematopoietic stem and progenitor cells (HSPCs) [29].   
Regulation of EMT by cell competition mechanisms 
There is new evidence elucidating the role of EMT in tumor heterogeneity, therapeutic resistance, and metastasis [53, 
65]. EMT is a complex process and is mediated by multiple transcription factor networks, and interestingly many of them are 
critical regulators of the cell competition mechanisms. Known EMT signaling pathways include Notch, Hedgehog, Hippo, and Wnt 
[66], all of which are known players in cell competition [67].  While Wnt/β-catenin is considered a significant signaling pathway 
required for the progression of colon cancer, a recent study demonstrated the role of hedgehog-GLI1 signaling (HH-GLI1) 
pathway in conferring winner phenotype to colon cancer stem cells through EMT and promote metastasis [68]. In Drosophila 
wing mosaics, Wg (Wnt homolog)-unresponsive cells are viable on their own but are eliminated by apoptosis when surrounding 
by Wg-responsive cells. 
Moreover, overactivation of the Wg pathway induced by axin or APC loss triggers apoptosis in neighboring wildtype 
wing disc cells [42, 69]. Thus, hyperactive Wnt signaling results in supercompetitor status. Work by DiMeo and colleagues found 
that tumor formation and lung metastasis were dependent on intact WNT signaling in mouse orthotopic human breast cancer 
model, and was required for cancer cell renewal and maintenance of dedifferentiated state including expression of Slug and 
Twist. Additionally, canonical WNT pathway signaling has been shown to induce EMT and enhance cell migration by stabilization 
of Snail and upregulation of Slug and Twist [70]. Whether Wnt-driven EMT programming is part of its competitive edge remains 
to be explored.  
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The Hippo pathway is a highly conserved signaling pathway that serves as the master regulator of organ size and tissue 
homeostasis by negatively regulating the function of YAP/TAZ. YAP/TAZ are transcriptional co-activators that positively regulate 
cell proliferation, cell size, and inhibit apoptosis.  [71]. YAP/TAZ has been found to induce EMT in human breast epithelial cells, 
but their specific target genes were not identified. Work by Christofori and colleagues showed that increased Tead2 expression 
resulted in enhanced YAP/TAZ nuclear localization and ultimately led to an invasive phenotype [72]. In T47D cell line, an ER+ 
breast cancer cell line, Hippo inactivation was required for Twist-mediated EMT, cancer cell invasion, and endowed cells with 
cancer stem cell-like properties [73]. Another possibility of altered Hippo pathway signaling is by loss of Scribble (Scrib), a tumor 
suppressor gene that negatively regulates Hippo downstream signaling. Scrib is required to establish apicobasal polarity and 
defective apicobasal polarity results in uncontrolled proliferation and acquisition of EMT characteristics [74]. Loss of Scrib has 
been a well-documented example of mechanotransduction-based cell competition [75-77]. In Drosophila, Scrib has been 
identified as a downstream target of Fat (Ft) receptor, a protein in the Hippo signaling pathway, and Ft requires Scrib to interact 
with other Hippo pathway members, to regulate Warts kinase activity and repress activation of Yorkie, a transcriptional co-
activator in Hippo signaling [78]. In Drosophila, the growth regulatory functions of Scrib required intact Hippo signaling [78]. In 
Drosophila imaginal discs, Scrib-/- cells display hyperactivated Yorkie resulting in large neoplasms. However, in mosaic wing discs 
comprised of both wildtype and Scrib-/- cells, normal cells suppress Yorkie activation and prevent overproliferation of Scrib-/- cells. 
Scrib-/- cells are subsequently outcompeted by wild-type cells and undergo JNK-mediated apoptosis [9]. Scrib likely relays similar 
signaling events related to cell competition in mammalian cells as evident from studies in MDCK cells. Loss of Scribble sensitizes 
cells to higher densities and co-culture of MDCK-WT with MDCK-scribble- knockdown (KD) compacts scribble KD cells, which 
eventually undergo apoptosis [77, 79]. Scrib-knockdown does not significantly affect MDCK cells when cultured alone, but when 
co-cultured with wildtype MDCK cells, Scrib-knockdown cells are highly sensitive to compaction and undergo p53-dependent 
apoptosis via p53-activation of Rho-associated kinase and p38, the stress kinase [77].  
Regulation of Immune by cell competition mechanisms 
Inflammatory processes are linked to breast cancer initiation and progression. Breast cancers frequently display an 
abundant population of infiltrating lymphocytes as a part of the host immune response to suppress the tumor. However, the 
tumor is frequently able to evade this immune response. It is important to explore whether this evasion is the result of cancer 
cells outcompeting specific subtypes of recruited immune cells. Two separate studies have shown that breast cancer cells 
overexpressing the death ligand, FasL (or CD95L), were found to induce apoptosis in the CD95+ stromal cell population [80, 81]. 
Increased FasL expression was observed in ductal carcinomas and hyperplastic breast tissues, but no expression was observed in 
healthy tissue. Apoptosis was specifically and predominantly found in the lymphocytic CD3+ cells as well as in blood vessels and 
fatty tissue adjacent to the tumor [81]. Moreover, the culture of CD95+ infiltrating lymphocytes with breast cancer sections 
induced apoptosis of the lymphocytes. This observation was reversed upon inhibition of CD95L by CD95-Fc fusion molecule [80]. 
Whether apoptosis of the immune cells was concomitant to enhanced proliferation of cancer cells remains to be uncovered. Still, 
these examples of cancer cell-induced elimination of immune cells represent one potential strategy mounted by tumor cells to 
escape immune surveillance. Cell competition, a homeostatic sensing mechanism, is conceptually very similar to the immune 
system recognition of “self“ from “non-self." 
In Drosophila, competition-induced elimination of loser clones is promoted by Toll innate immune signaling. The two 
crucial cell competition genes Myc and Minute which are required for elimination of the loser cells, both use the related but 
distinct components of the immune deficiency (IMD) and Toll pathways [82]. The standard features in signaling pathways 
required for elimination of loser clones are involvement of Spätzle (an extracellular ligand), noncanonical Toll-related receptors 
(TRRs) and NFkB-induced apoptosis. The elimination of loser cells in Myc-induced cell competition model requires Toll-2, Toll-3, 
Toll-8, and Toll-9, and activation of Relish. However, elimination of loser cells generated in the Minute mutation model required 
Toll-3 and Toll-9 along with Dorsal and Dif [82]. These results suggest that the genetic identity between competing cells 
determines the activated signaling pathways. Secondly, these findings suggest that cell competition is an active mechanism built 
within the innate immune system to remove less fit cells [82]. Although not experimentally demonstrated, cell competition 
mechanisms could explain for immune cell heterogeneity in tumors where a dominant tumor clone with a distinct metabolic 
profile (likely glycolytic) may evade killing by T cells, whereas tumor cells without such metabolic adaptation became a loser 
clone and eliminated by T cells [83]. The current theory is that dominant clones with higher glycolytic activity express reduced 
levels of IRF1 and CXCL10 immunostimulatory molecules and thus enabling them to avoid recognition by T-cells. However, we 
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propose an alternative possibility that cell competition could play a significant role in determining the therapeutic response to 
cancer immunotherapy and developing assays to identify Winner and Loser tumor clones and competition between cancer cells 
and immune cells could further increase the success of immunotherapy. 
CONCLUSION 
The scope of this article is to bring to light the recent advances made in the field of cell competition, specifically in 
mammalian research. In recent years, important advances have been made in elucidating the role of cell competition in 
oncogenesis and metastasis. Clonal dynamics and cell-cell interactions within a heterogeneous tumor remains a significant 
challenge to fully decode, given the enormous complexity. Herein, we extend the recent findings in cell competition, and 
elucidation of various pathways, as potential mechanisms governing cell selection and contribution to the heterogeneous tumor 
space. In addition to playing the role of a tumor suppressor during early stages of cancer initiation, cell competition can drive 
tumor progression via proposed formation of super competent cancer cells [10, 12]. The theory postulated that cancerous cells 
acquire the super-competent phenotype by steadily accumulating genomic aberrations where they can promote the death of 
surrounding healthy cells and via this process, initiate and promote oncogenesis. Research in recent years has presented strong 
physiological and genetic evidence in support of this hypothesis. The notable advances include 1) identification of genomic 
aberrations and signaling networks enriched in winner cells (cMyc, YAP/TAZ, p53 mutation, and other genes discussed in the 
review); 2) cell competition is not confined to epithelial compartment as completion could occur between cancer cells and 
stromal cells; 3) cell competition as another mechanism of clonal dominance; and 4) role of cell competition in therapeutic 
resistance and metastasis. These advances also prepare preliminary steps towards exploring the role of cell competition in the 
design of anti-cancer therapy options, particularly immunotherapies. For example, results showing that inhibition of cell 
competition-induced apoptosis in simulated precancerous lesions would result in suspended cell death in surrounding healthy 
tissue and thus diminished tumorigenesis, are very encouraging [61]. Besides, a sizeable number of genetic targets have been 
identified to participate in both pro- and anti-cancer competition pathways, and we predict soon their role in the fight against 
cancer will be explored. Future studies focused on thorough investigations of cell competition pathways in the context of 
oncogenic signaling are paramount and would open new doors for cancer therapies.  
 
 
 
 
FIGURE LEGENDS 
Fig 1. The illustration on the left describes a model explaining the process through which cell competition promotes tumor 
growth and metastasis. During the early stages of oncogenesis, cell competition may function as a tumor-promoting 
mechanism and promotes survival and spread of oncogenic cells. To propagate through the affected organ and form 
pre-cancerous fields, the cancer cells outcompete the surrounding healthy cells, eliminate them, and in the process, 
create space and availability of nutrients for their propagation. The illustration on the right describes how at advanced 
cancer stages, the same principle of competition-dependent elimination of host cells by cancer cells promotes the 
escape of neoplastic cells from the cancer mass, which results in clinically relevant metastasis.  
Fig 2. In this figure, the role of cell competition in tumor growth is illustrated from a detailed analysis of the hematoxylin and 
eosin (H&E) stained colon adenocarcinoma, ovarian serous high-grade carcinoma, and pancreatic ductal carcinoma 
sections. All cancers show the clear tumor and stromal regions which have the potential to compete with each other. 
The cancer mass appears to be heterogeneous with cells are at different stages. The stromal or microenvironment 
region is marked and represents its cell populations such as fibroblasts, B cells, T cells, endothelial, and epithelial cells, 
amongst other cell types. At the bottom, a graphical depiction demonstrates the possible role of cell competition 
between cancer cells and their surrounding heterogeneous tumor microenvironment. The growth of cancer in the 
affected organ depends on its ability to create space and availability of nutrients by progressive elimination of the 
stromal cells throughout cancer life-cycle. Recent literature presents evidence for the role of several genes labeled in 
the figure, which play a role in determining the outcome of the oncogenic fate. These cell competition associated genes 
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determine if the cancer cells will be able to outcompete the stromal cells and propagate or the stromal cells will be able 
to prevent their elimination and stop cancer growth by mounting localized anti-tumor response. 
Fig 3. The model explains the role of intra-tumoral cell competition in enhancing the aggressiveness of cancer over time. The 
tumoral mass, which comprises of a genetically heterogeneous array of cancer cells continues to gain traits of 
aggression in patients with passing time. We hypothesize that the cancer cells of multiple lineages carry traits of pre-
determined or acquired competence-levels and these cancer cells keep comparing their relative fitness levels during the 
period of co-existence within the tumor mass. The cells with higher competence try and outcompete cells with lower 
competence and, in this process, continuously strive to conserve and propagate the most aggressive genotypic and 
phenotypic attributes of cancer. The H&E section of a pancreatic ductal carcinoma highlights some aggressive cancer 
cells which as per our hypothesis over time would continue to propagate themselves in this cancer mass, and this might 
be facilitated by intra-tumoral competition with other cells with lower competence. This hypothesis is presented as a 
graphic illustration below the H&E stained slides.  
Fig 4. Model 4 presents a plausible scenario highlighting the role of cells in the tumor microenvironment in regulating the 
ability of cancer cells to form heterogenous pre-cancerous fields. The first case (left): Where the tumor 
microenvironment cells of multiple origins (as shown in the figure) are with high fitness status or are expressing marks 
of high competitiveness. These cells encounter a heterogeneous population of cancer cells which try to expand in this 
tissue space. These cancer cells have three evolutionary battles to fight, a) selection of most competent cancer cell 
subtypes amongst all cancer cell populations, b) selected cancer sub-populations to remain viable by regulating 
competition-based interactions with the tumor microenvironment cells, and c) selected and viable cancer cell sub-
populations to outcompete and eliminate the tumor microenvironment cells in order to gain space and nutrition to 
form pre-cancerous fields. In the presence of tumor microenvironment cells with high fitness levels, the selected cancer 
cells lose their other 2 battles, and thus, the organs or host tissues can protect themselves from oncogenic invasions. 
The second case (right): In a scenario where the tumor microenvironment cells are less fit owing to any physiological or 
genetic reasons. These tumor microenvironment cells have a significant impact on the regulation of tumor genetic 
heterogeneity.  Here 3 forms of competition battles seem to be unfolding, a) selection of most competent cancer cell 
subtypes amongst all cancer cell populations, which converts into a long-term evolutionary process because in this 
scenario pre-cancerous fields are formed which turn into clinically relevant cancers after a number of years, b) because 
tumor microenvironment cells have reduced fitness levels they rarely impact viability and proliferation of most cancer 
cells. Thus they undergo elimination and provide assistance to the formation of pre-cancerous fields, and c) because 
fitness is a relative concept, these low-fitness tumor microenvironment cells eliminate any  cells which may have poor 
fitness status but collectively allows all the available cancer sub-populations to thrive and proliferate, resulting in a 
diversification of the genetic background of the cancer cells constituting the pre-cancerous fields.  
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Figure 1: Cell competition between tumor and host cells promotes cancer growth and metastasis
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Figure 2: Tumor-stromal interface and complexity of microenvironment in human cancers.
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Figure 3: Intra-tumoral cell competition can increase aggressive phenotype of the cancer.
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Figure 4: Fitness of microenvironment determines fate of cancer.
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